• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Martucci Walter Edward Ii was granted 3,097,928 shares

    11/4/22 6:59:24 PM ET
    $DNAA
    Get the next $DNAA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Martucci Walter Edward II

    (Last) (First) (Middle)
    C/O AKILI, INC.
    125 BROAD STREET, FIFTH FLOOR

    (Street)
    BOSTON MA 02110

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Akili, Inc. [ AKLI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    11/02/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/02/2022 A 109,096 A (1) 109,096 D
    Common Stock 11/02/2022 A 2,988,832 A (2) 3,097,928 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $2.3 11/02/2022 A 442,995 (3) 11/02/2032 Common Stock 442,995 $0.00 442,995 D
    Explanation of Responses:
    1. Represents a grant of restricted stock units ("RSUs") under the Akili, Inc. 2022 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 16.67% of the RSUs underlying this grant shall vest on May 2, 2023, with an additional 16.67% vesting at the end of each six (6) month period thereafter, subject to the reporting person's continued service on each such vesting date.
    2. Represents a grant of RSUs under the Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs underlying this grant shall vest upon the Issuer's common stock achieving certain specified prices per share, subject to the reporting person's continued service at such time.
    3. 16.67% of the shares underlying this option shall vest and become exercisable on May 2, 2023, with an additional 16.67% vesting at the end of each six (6) month period thereafter, subject to the reporting person's continued service on each such vesting date.
    Remarks:
    /s/ Jacqueline Studer, attorney-in-fact 11/04/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DNAA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DNAA
    SEC Filings

    See more
    • SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

      424B3 - Akili, Inc. (0001850266) (Filer)

      1/12/23 8:13:45 AM ET
      $DNAA
    • Social Capital Suvretta Holdings Corp. I filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Akili, Inc. (0001850266) (Filer)

      1/12/23 8:06:32 AM ET
      $DNAA
    • SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

      424B3 - Akili, Inc. (0001850266) (Filer)

      1/5/23 7:21:42 AM ET
      $DNAA

    $DNAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Jina Anil (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:14:59 PM ET
      $DNAA
    • SEC Form 3 filed by new insider Ehlert Kenneth (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:15:13 PM ET
      $DNAA
    • SEC Form 3 filed by new insider Martucci Walter Edward Ii (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:10:52 PM ET
      $DNAA

    $DNAA
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer

      Jon David brings deep expertise in building and launching engaging products to the Akili leadership team PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where

      3/17/22 9:05:00 AM ET
      $DNAA
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer

      Jon David brings deep expertise in building and launching engaging products to the Akili leadership team Akili Interactive ("Akili" or the "Company"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where the treatment is experienced like high-end entertainment. Reporting to the CEO, David will join the Akili executive team, which includes leader

      3/17/22 9:00:00 AM ET
      $DNAA